(UroToday.com) The 2025 PSMA and Beyond annual meeting featured new developments in genitourinary radioligand therapy session and a presentation by Dr. Robert Flavell discussing STEAP1, DLL3, and CD46 ...
(UroToday.com) The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a phase II trial of cabozantinib in relapsed refractory germ cell ...
(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a surgical and non-surgical treatment of non muscle invasive bladder cancer session and a presentation by Dr.
At the 2026 UCSF-UCLA PSMA Conference, Lisa Bodei reviews PSMA response biomarkers for lutetium PSMA therapy. She presents data from the TheraP and VISION trials showing that baseline SUV mean, ...
(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a urology trials in bladder and prostate cancer session and a presentation by Dr. Yi-Jun Shen discussing HERO, a ...
ASCO 2025 Press Releases Johnson & Johnson Leads with First PARP Inhibitor Combo to Improve Efficacy in Patients with HRR-altered mCSPC ImmunityBio Receives FDA Expanded Access Authorization for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results